Host: Linda Stein Gold, MD

Guest: Keri Holyoak, PA-C, MPH

When it comes to psoriasis, it’s important to not just treat the skin, but also the patient as a whole. That’s why Dr. Linda Stein Gold and Keri Holyoak are here to discuss the often-overlooked psychosocial burden of psoriasis and how we can talk to our patients about their mental health.

Host: Linda Stein Gold, MD

Guest: Jonathan S. Weiss, MD

Our understanding of the pathogenesis and pathophysiology of psoriasis continues to evolve, with one of the more recent pathways identified being the aryl hydrocarbon receptor. Here to share what we currently know about the role of the aryl hydrocarbon receptor in psoriasis are Dr. Linda Stein Gold and Jonathan Weiss.

Host: Hector O. Chapa, MD, FACOG

Guest: Linda Ahn, MD, FACOG

Amid growing evidence that infection with high-risk HPV can increase the risk of cervical cancer, the American College of Obstetricians and Gynecologists, the American Society for Colposcopy and Cervical Pathology, and the American Cancer Society have all updated their guidelines to help identify patients at risk while reducing unnecessary invasive procedures and over-testing. Joining Dr. Hector Chapa to walk us through these guidelines is board-certified obstetrician/gynecologist Dr. Linda Ahn.

Guest: Norman Lepor, MD, FACC, FAHA, FSCAI

Tune in to hear Dr. Norman Lepor from the UCLA Geffen School of Medicine discuss the role of LDL-C and comorbidities in atherosclerotic cardiovascular disease (ASCVD) risk assessment as well as the limitations of statin treatment.

10/21 121913

NUCALA (mepolizumab) is for the add-on treatment of patients 6+ with severe eosinophilic asthma. Not for acute bronchospasm or status asthmaticus.

Please See Important Safety Information Below

Every patient with severe eosinophilic asthma has different kinds of needs, which is why it's important to have a treatment available that has options. With the NUCALA Autoinjector, clinicians have the power to choose at-home or in-office administration for appropriate patients aged 12 years and older. Could NUCALA make a difference for your patients?

MPLWCNT210112 October 2021
Produced in USA.

NUCALA (mepolizumab) is for the add-on treatment of patients 6+ with severe eosinophilic asthma. Not for acute bronchospasm or status asthmaticus.

Please See Important Safety Information Below

From spending time on the driving range to sitting at home instead of the waiting room, learn what the NUCALA Autoinjector can mean for your patients.

MPLWCNT210111 October 2021
Produced in USA.

Guest: Rami Komrokji, MD

Guest: Natasha Johnson, MSN, APRN, AOCNP

Myelodysplastic syndromes (MDS) can require lifelong treatment.1 Learn how hematologist-oncologist Dr. Rami Komrokji and nurse practitioner Ms. Natasha Johnson approach their MDS protocol–from characterization, to diagnosis, to treatment. Together, they explain their process for scoring, transplants, and choosing a treatment regimen. They also share their experiences with INQOVI® (decitabine and cedazuridine), the only oral hypomethylating agent in the treatment of MDS, including chronic myelomonocytic leukemia.2

References: 1. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107. 2. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.

Guest: Ashley Moncrief, RN, BSN

Guest: Natasha Johnson, MSN, APRN, AOCNP

Tune in to hear nurse practitioners Ms. Natasha Johnson and Ms. Ashley Moncrief discuss myelodysplastic syndromes (MDS), a rare type of blood cancer, and how it is classified and identified. Together, they share personal experiences from their practices and tips for conversations with MDS patients about their care.

© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0390

Host: Jennifer Caudle, DO

Guest: Mark Socinski, MD

Dr. Mark Socinski from the AdventHealth Cancer Institute in Florida joins Dr. Jennifer Caudle to discuss a patient profile in the treatment of relapsed small cell lung cancer to help us better understand the burden of this disease and how to approach treating patients in the second-line setting with treatment options like ZEPZELCA.

Guest: Azra Raza, MD

Guest: Rami Komrokji, MD

Listen to hematologist-oncologists Drs. Rami Komrokji and Azra Raza discuss myelodysplastic syndromes (MDS). Together, they explain the classification system for diagnosing this rare blood disorder and touch upon current events in the space and the impact on patients living with MDS.

© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0384